Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Controlled-phase Gate for Photons Based on Stationary Light.

Iakoupov I, Borregaard J, Sørensen AS.

Phys Rev Lett. 2018 Jan 5;120(1):010502. doi: 10.1103/PhysRevLett.120.010502.

PMID:
29350945
2.

Topological Quantum Optics in Two-Dimensional Atomic Arrays.

Perczel J, Borregaard J, Chang DE, Pichler H, Yelin SF, Zoller P, Lukin MD.

Phys Rev Lett. 2017 Jul 14;119(2):023603. doi: 10.1103/PhysRevLett.119.023603. Epub 2017 Jul 14.

PMID:
28753358
3.

Clinical Pharmacology in Denmark in 2016 - 40 Years with the Danish Society of Clinical Pharmacology and 20 Years as a Medical Speciality.

Brøsen K, Andersen SE, Borregaard J, Christensen HR, Christensen PM, Dalhoff KP, Damkier P, Hallas J, Heisterberg J, Jessen N, Jürgens G, Kampmann JP, Laursen BE, Laursen T, Nielsen LP, Poulsen BK, Poulsen HE, Andersen LV, Senderovitz T, Sonne J.

Basic Clin Pharmacol Toxicol. 2016 Dec;119(6):523-532. doi: 10.1111/bcpt.12681. Epub 2016 Oct 23. Review.

4.

An integrated diamond nanophotonics platform for quantum-optical networks.

Sipahigil A, Evans RE, Sukachev DD, Burek MJ, Borregaard J, Bhaskar MK, Nguyen CT, Pacheco JL, Atikian HA, Meuwly C, Camacho RM, Jelezko F, Bielejec E, Park H, Lončar M, Lukin MD.

Science. 2016 Nov 18;354(6314):847-850. Epub 2016 Oct 13.

PMID:
27738014
5.

Scalable photonic network architecture based on motional averaging in room temperature gas.

Borregaard J, Zugenmaier M, Petersen JM, Shen H, Vasilakis G, Jensen K, Polzik ES, Sørensen AS.

Nat Commun. 2016 Apr 14;7:11356. doi: 10.1038/ncomms11356.

6.

Heralded quantum gates with integrated error detection in optical cavities.

Borregaard J, Kómár P, Kessler EM, Sørensen AS, Lukin MD.

Phys Rev Lett. 2015 Mar 20;114(11):110502. Epub 2015 Mar 17.

PMID:
25839248
7.

The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.

Tzogani K, Skibeli V, Westgaard I, Dalhus M, Thoresen H, Slot KB, Damkier P, Hofland K, Borregaard J, Ersbøll J, Salmonson T, Pieters R, Sylvester R, Mickisch G, Bergh J, Pignatti F.

Oncologist. 2015 Feb;20(2):196-201. doi: 10.1634/theoncologist.2014-0177. Epub 2015 Jan 23. Review.

8.

The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Boix-Perales H, Borregaard J, Jensen KB, Ersbøll J, Galluzzo S, Giuliani R, Ciceroni C, Melchiorri D, Salmonson T, Bergh J, Schellens JH, Pignatti F.

Oncologist. 2014 Jul;19(7):766-73. doi: 10.1634/theoncologist.2013-0348. Epub 2014 Jun 13. Review.

9.

Efficient atomic clocks operated with several atomic ensembles.

Borregaard J, Sørensen AS.

Phys Rev Lett. 2013 Aug 30;111(9):090802. Epub 2013 Aug 27.

PMID:
24033017
10.

Near-Heisenberg-limited atomic clocks in the presence of decoherence.

Borregaard J, Sørensen AS.

Phys Rev Lett. 2013 Aug 30;111(9):090801. Epub 2013 Aug 27.

PMID:
24033016
11.

The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersbøll J, Abadie E, Giuliani R, Pignatti F.

Clin Cancer Res. 2012 Sep 1;18(17):4491-7. doi: 10.1158/1078-0432.CCR-11-3075. Epub 2012 Jul 24.

12.

The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.

Nieto M, Borregaard J, Ersbøll J, ten Bosch GJ, van Zwieten-Boot B, Abadie E, Schellens JH, Pignatti F.

Clin Cancer Res. 2011 Nov 1;17(21):6608-14. doi: 10.1158/1078-0432.CCR-11-1734. Epub 2011 Oct 5. Review.

13.

Evaluation of the effect of the specific CCR1 antagonist CP-481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects.

Borregaard J, Skov L, Wang L, Ting N, Wang C, Beck LA, Sonne J, Clucas A.

Contact Dermatitis. 2008 Oct;59(4):212-9. doi: 10.1111/j.1600-0536.2008.01365.x.

PMID:
18844696

Supplemental Content

Loading ...
Support Center